《生命科学》 2023, 35(1): 80-87

2022年新药研发发展态势

李　荣¹ , 孟　晶² , 赵若春¹ , 韩　佳¹ , 马征远¹ , 陈大明^1,*

¹中国科学院上海营养与健康研究所，中国科学院上海生命科学信息中心， 上海 200031 ²同济大学附属第一妇婴保健院，上海 201306

摘　要：

新药研发作为医药产业中的重要环节，是医药产业发展升级的关键环节。近几年，源头技术的突破、多学科交叉整合的创新，促成了新药研发的快速发展。2022 年以来，全球新药研发模式加速演进，获批上市的新药类别不断丰富，抗体药、细胞与基因治疗药物快速发展，一批重磅新药的上市给复杂疾病的诊治带来了新希望。本文从获批上市药物类别、新技术驱动新药开发等视角出发，对2022 年新药研发的进展进
行了综述，以期为后续研究提供参考。

通讯作者：陈大明 , Email:chendaming@sinh.ac.cn

Analysis of research and development status of new drugs in 2022

LI Rong¹ , MENG Jing² , ZHAO Ruo-Chun¹ , HAN Jia¹ , MA Zheng-Yuan¹ , CHEN Da-Ming^1,*

¹Shanghai Information Center for Life Sciences, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai 200031, China ²Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai 200092, China

Abstract:

As an important role in the pharmaceutical industry, new drugs research and development (R&D) is a key node in the upgrading of the pharmaceutical industry. In recent years, with the breakthrough of source technology and the innovation of multidisciplinary integration, new drugs R&D develops rapidly. In 2022, global new drugs R&D mode accelerated, and there were a wide variety of new drugs approved for marketing, such as antibody drugs, cell and gene therapy drugs and so on. The launch of a variety of significant new drugs has brought hope for the diagnosis and treatment of complex diseases. This article reviews the research progress of new drugs R&D in 2022 from the perspectives of approved drugs categories and new technology-driven new drugs R&D, in order to provide a reference for follow-up R&D.

Communication Author：CHEN Da-Ming , Email:chendaming@sinh.ac.cn